Primary Mitochondrial Myopathy Drug Fast Tracked by FDA


Elamipretide treats rare genetic disorder that causes muscle weakness and severe fatigue.

The FDA has granted Fast Track designation for a drug candidate designed to help patients suffering from primary mitochondrial myopathy.

Stealth BioTherapeutics developed the drug elamipretide, formerly known as Bendavia, in hopes to treat this rare genetic disorder that impairs health with muscle weakness and severe fatigue. Currently there are no FDA approved medications.

Researchers from the Institut de recherches cliniques de Montréal (IRCM) discovered a family of molecules, elamipretide being among them.

“Elamipretide targets the inner mitochondrial membrane and helps preserve mitochondrial energetics,” said drug discoverer Peter W. Schiller, PhD. “Due to this property, elamipretide could become the first treatment designed for primary mitochondrial myopathy. The FDA’s grant of a Fast Track designation for this treatment is therefore excellent news.”

The FDA’s Fast Track program increases the likelihood for eligibility of priority review and accelerated approval if certain criteria is met for these drugs that treat serious conditions.

Related Videos
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson |
pain management palliative care/Image Credits: © Aleksej -
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 |
palliative and hospice care/ Image Credits: © David Pereiras -
Young woman using smart phone,Social media concept. - Image credit: Urupong |
© 2024 MJH Life Sciences

All rights reserved.